Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions

Claim 2

A reconstituted lyophilized formulation of polyethylene glycol and a biologically active catalase conjugate comprising: a) polyethylene glycol having a molecular weight of from about 1,000 to about 15,000 daltons and consisting of less than about 10% w/w non-monomethoxylated polyethylene glycol and more than 90% w/w monomethoxylated polyethylene glycol; said conjugate having an enzymatic activity of from about 150 to about 150,000 U/ml; b) from about 0.1 to about 20% w/v of cyclodextrin; and c) from about 0.01 to about 50 nM buffer, said formulation having a pH of from about 5.7 to about 6.5.

Claim 3

The reconstituted lyophilized formulation of claim 1 wherein said conjugate has an enzymatic activity of from about 25,000 to about 150,000 U/ml.

Claim 4

The reconstituted lyophilized formulation of claim 1 wherein said conjugate has an enzymatic activity of from about 50,000 to about 150,000 U/ml.

Claim 5

The reconstituted lyophilized formulation of claim 1 wherein said cyclodextrin is present in an amount of from about 1.0 to about 15% w/v.

Claim 6

The reconstituted lyophilized formulation of claim 1 wherein said cyclodextrin is present in an amount of from about 5 to about 10% w/v.

Claim 7

The lyophilized formulation of claim 1 wherein said polyethylene glycol has an average molecular weight of from about 2,000 to about 10,000 daltons.

Claim 8

The lyophilized formulation of claim 1 wherein said polyethylene glycol has an average molecular weight of from about 4,000 to about 6,000 daltons.

Claim 9

The lyophilized formulation of claim 1 wherein said polyethylene glycol contains less than about 7% w/w non-monomethoxylated polyethylene glycol.

Claim 10

The lyophilized formulation of claim 1 wherein said polyethylene glycol contains less than about 5% w/w non-monomethoxylated polyethylene glycol.

Claim 11

The lyophilized formulation of claim 1 wherein said cyclodextrin is a derivative of β-cyclodextrin.

Claim 12

The lyophilized formulation of claim 10 wherein said β-cyclodextrin derivative is hydroxypropyl cyclodextrin.

Claim 13

The lyophilized formulation of claim 10 wherein said β-cyclodextrin derivative is glucosyl cyclodextrin.

Claim 14

The lyophilized formulation of claim 10 wherein said β-cyclodextrin derivative is maltosyl cyclodextrin.

Claim 15

The lyophilized formulation of claim 10 wherein said β-cyclodextrin derivative is maltotriosyl cyclodextrin.

Claim 16

The lyophilized formulation of claim 1 wherein said catalase is bovine hepatocatalase.

Claim 17

A process of preparing a lyophilized biologically active catalase composition comprising the steps of: a) carboxylating polyethylene glycol containing less than 10% w/w non-monomethoxylated polyethylene glycol; b) activating said carboxylated polyethylene glycol to obtain an active polyethylene glycol ester; c) covalently attaching said active polyethylene glycol ester to a biologically active catalase; d) solubilizing said covalently attached polyethylene glycol ester and said biologically active catalase in an aqueous media; e) solubilizing cyclodextrin in said aqueous media to obtain a homogeneous solution; f) buffering said solution to a pH of from about 5.7 to about 6.5; and h) lyophilizing the solution.

Claim 18

A process of preparing a lyophilized biologically active catalase composition comprising the steps of: a) carboxylating polyethylene glycol containing less than 10% w/w non-monomethoxylated polyethylene glycol; b) activating said carboxylated polyethylene glycol to obtain an active polyethylene glycol ester; c) covalently attaching said active polyethylene glycol ester to a biologically active catalase; d) solubilizing said covalently attached polyethylene glycol ester and said biologically active catalase in an aqueous media; e) solubilizing cyclodextrin in said aqueous media to obtain a homogeneous solution; f) buffering said solution to a pH of from about 5.7 to about 6.5; and h) lyophilizing the solution.

Claim 19

The process of claim 16 wherein said solution for lyophilization comprises: from about 150 to about 150,000 unit/ml of a covalently bound low diol polyethylene glycol/catalase; from about 0.1 to about 20% w/v of cyclodextrin; and from about 0.01 to about 50 mM of a buffer.

Claim 20

The process of claim 16 wherein said polyethylene glycol has an average molecular weight of from about 1,000 to about 15,000 daltons.

Claim 21

The process of claim 16 wherein said cyclodextrin is a derivative of β-cyclodextrin.

Claim 22

The process of claim 19 wherein said β-cyclodextrin derivative is hydroxypropyl cyclodextrin.

Claim 23

The process of claim 19 wherein said β-cyclodextrin derivative is maltosyl cyclodextrin.

Claim 24

The process of claim 19 wherein said β-cyclodextrin derivative is maltotriosyl cyclodextrin.

Claim 25

A method of treating a disease condition caused by hydrogen peroxide anions on tissue in a mammal comprising administering an effective amount of a composition according to claim 1.

Claim 26

The method of claim 23 wherein said disease condition is inflammation.

Claim 27

The method of claim 23 wherein said disease condition is ischemia.

Claim 28

The method of claim 23 wherein said disease condition is reperfusion injury.

Claim 29

The method of claim 23 wherein said disease condition is trauma.

Claim 30

The method of claim 23 wherein said disease condition is stroke.